Aquestive Therapeutics (AQST) Stock Forecast & Price Target
Score
Aquestive Therapeutics, Inc. price target
| AQST | |
|---|---|
| Low | $10.00 |
| Average | $10.50 |
| High | $11.00 |
| Upside vs current price | +168.5% |
The average target of $10.50 is +168.5% versus the current AQST price of $3.91.
Aquestive Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 2 |
| Buy | 7 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
9 analysts cover AQST.
Aquestive Therapeutics, Inc. EPS and revenue estimates
The estimate table for the Aquestive Therapeutics, Inc. keeps 2026 EPS $-0.47, 2027 EPS $-0.49, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-0.47 | $49.50M |
| 2027 | $-0.49 | $67.91M |
Is Aquestive Therapeutics, Inc. a buy or sell?
Of the 9 analysts covering Aquestive Therapeutics, Inc., 9 rate it a buy (2 strong buy and 7 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The AQST consensus label is Buy, beside 9 buy-side ratings and 0 sell-side ratings.
The average target of $10.50 implies +168.5% versus the current price of $3.91.
the Aquestive Therapeutics, Inc. closes with 9 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Aquestive Therapeutics, Inc. forecast
There is little daylight between AQST targets. Low $10.00, average $10.50, high $11.00.
From today's $3.91 print, the AQST average target is +168.5% away.
Most of the AQST coverage agrees: 9 of 9 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
AQST targets have eased: $10.00 in the last month against $10.50 over the last quarter.
AQST coverage is thin at 9 analysts, and one revision moves the average.
Aquestive Therapeutics, Inc. forecast questions
What is the AQST price target?
The published range for AQST is $10.00 to $11.00, with an average of $10.50. That average is +168.5% versus the current price of $3.91.
Is Aquestive Therapeutics, Inc. a buy or sell?
Of the 9 analysts covering Aquestive Therapeutics, Inc., 9 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for AQST is 9 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for Aquestive Therapeutics, Inc.?
Analyst EPS estimates for Aquestive Therapeutics, Inc.: 2026 $-0.47, 2027 $-0.49.
What is the revenue estimate for Aquestive Therapeutics, Inc.?
Analyst revenue estimates for Aquestive Therapeutics, Inc.: 2026 $49.50M, 2027 $67.91M.
How many analysts cover AQST?
9 analysts cover AQST. Their consensus on AQST is Buy, across those 9.